Integrated Biopharma, Inc.
INBP
$0.3069
$0.01194.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 130.37% | 538.98% | 570.00% | 1,681.25% | -594.55% |
| Total Depreciation and Amortization | 5.30% | 7.38% | 6.02% | 1.33% | 6.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,488.89% | 208.54% | 20.87% | 69.05% | -110.00% |
| Change in Net Operating Assets | 79.40% | -117.64% | 44.51% | -14.77% | -380.11% |
| Cash from Operations | 111.00% | -49.96% | 84.32% | 11.77% | -4,052.27% |
| Capital Expenditure | -20.83% | -47.37% | -711.11% | -2,056.25% | 25.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -20.83% | -47.37% | -758.82% | -2,056.25% | 14.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 30.00% | -10.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 263.64% | -333.33% | -10.00% | 0.00% | 0.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 110.20% | -53.52% | 71.72% | -10.80% | -2,143.37% |
